World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
44
Citations
17791
World Ranking
5070
National Ranking
64

Overview

Mauro Schechter is affiliated with the Federal University of Rio de Janeiro in Brazil and has contributed extensively to medical research, particularly in the fields of HIV and infectious diseases. Their scholarly work spans multiple disciplines including Medicine and Immunology and Microbiology, with a focus on several subfields such as Virology, Infectious Diseases, Molecular Biology, Pediatrics, Perinatology and Child Health, and Epidemiology.

Their research primarily addresses issues related to HIV research and treatment, including HIV/AIDS drug development and treatment protocols. Other significant topics of investigation include poxvirus research and outbreaks, studies on Bacillus and Francisella bacterial species, pharmacological effects and toxicity studies, herpesvirus infections and treatments, and broader viral infections and outbreak research.

Mauro Schechter's frequent coauthors include Jürgen K. Rockstroh, Bonaventura Clotet, José Luís Blanco, Alexandra Calmy, and Laura Waters. This network of collaborators points to a strong presence within international research communities focusing on infectious diseases and virology.

The scientist's publications are distributed among several notable venues, reflecting the multidisciplinary nature of their work. Their most common publication outlet is UNC Libraries, followed by contributions to The Lancet, Clinical Infectious Diseases, Journal of Virus Eradication, and PLOS Global Public Health.

Recent papers by Mauro Schechter include the following:

  • Mpox in people with advanced HIV infection: a global case series, 2023, The Lancet
  • Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk, 2022, Clinical Infectious Diseases
  • Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial, 2024, Journal of Virus Eradication
  • International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreak, 2025, PLOS Global Public Health
  • Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection, 2020, UNC Libraries

Best Publications

  • Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

    Robert M. Grant;Javier R. Lama;Peter L. Anderson;Vanessa McMahan

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study

    Robert M. Grant;Robert M. Grant;Robert M. Grant;Peter L. Anderson;Vanessa McMahan;Albert Liu

  • Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

    P Braitstein;Mwg Brinkhof;F Dabis;M Schechter

  • Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

    Peter L. Anderson;David V. Glidden;Albert Liu;Susan Buchbinder

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

    Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel

    Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

    Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

    Frederick L Altice;Frederick L Altice;Adeeba Kamarulzaman;Vincent V Soriano;Mauro Schechter

  • Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission

    Linda Gail Bekker;Linda Gail Bekker;George Alleyne;Stefan Baral;Javier Cepeda

  • Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries

    Martin W. G. Brinkhof;François Dabis;Landon Myer;David R. Bangsberg

  • Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.

    Alison J. Rodger;Rebecca Lodwick;Mauro Schechter;Steven Deeks

  • Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected Persons: An International Randomized Trial

    F Gordin;R E Chaisson;J P Matts;C Miller

  • Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

    Scott M Hammer;Michael S Saag;Mauro Schechter;Julio S G Montaner

  • HIV-1 DNA predicts disease progression and post-treatment virological control

    James P Williams;Jacob Hurst;Jacob Hurst;Wolfgang Stöhr;Nicola Robinson;Nicola Robinson

  • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

    Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  • Behavioral Impact, Acceptability, and HIV Incidence among Homosexual Men with Access to Postexposure Chemoprophylaxis for HIV

    Mauro Schechter;Regina F. Do Lago;Aaron B. Mendelsohn;Ronaldo I. Moreira

  • Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

    Roy T. Steigbigel;David A. Cooper;Hedy Teppler;Joseph J. Eron

  • Manual de HIV/AIDS

    Marcia Rachid;Mauro Schechter

  • Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

    Christine Katlama;Richard Haubrich;Jacob Lalezari;Adriano Lazzarin

  • Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.

    Denis Nash;Monica Katyal;Martin W.G. Brinkhof;Olivia Keiser

  • Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

    Jacob Hurst;Matthias Hoffmann;Matthew Pace;Matthew Pace;James P. Williams

  • Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

    Kathleen Mulligan;David V. Glidden;Peter L. Anderson;Albert Liu

  • Community-based interventions to improve and sustain antiretroviral therapy adherence, retention in HIV care and clinical outcomes in low- and middle-income countries for achieving the UNAIDS 90-90-90 targets

    Jean B. Nachega;Jean B. Nachega;Jean B. Nachega;Olatunji Adetokunboh;Olalekan A. Uthman;Olalekan A. Uthman;Amy W. Knowlton

Frequent Co-Authors

Lee H. Harrison
Lee H. Harrison University of Pittsburgh
Robert M. Grant
Robert M. Grant University of California, San Francisco
David A. Cooper
David A. Cooper University of New South Wales
Matthias Egger
Matthias Egger University of Bern
Linda-Gail Bekker
Linda-Gail Bekker University of Cape Town
François Dabis
François Dabis University of Bordeaux
David V. Glidden
David V. Glidden University of California, San Francisco
Kenneth H. Mayer
Kenneth H. Mayer Harvard Medical School
Susan Buchbinder
Susan Buchbinder University of California, San Francisco
Paula Braitstein
Paula Braitstein University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers related to Microbiology often includes options in healthcare administration and medical coding. For those interested in healthcare documentation and coding, earning a cpc certification salary reflects the growing demand for certified professional coders. This credential can open doors to stable and rewarding career paths within medical billing and health information management.

Health Information Management (HIM) is another promising field, combining data management with healthcare expertise. An essential step is choosing a cahiim accredited him degree online, which ensures your education meets industry standards and increases employability. Graduates often find competitive roles with attractive health information management degree salary prospects.

For those seeking a quicker entry into the field, a fast track medical billing and coding certificate online program can be an efficient way to build foundational skills. These accelerated options provide valuable credentials that help jumpstart a career in medical billing, coding, and health information processing—fields closely linked to microbiology in healthcare environments.

Best Scientists Citing Mauro Schechter

Trending Scientists

Recently Published Articles